Alexion Pharmaceuticals (ALXN) Given Buy Rating at Cowen

Cowen reissued their buy rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research note released on Wednesday morning. They currently have a $165.00 price target on the biopharmaceutical company’s stock.

Several other analysts have also issued reports on ALXN. Oppenheimer set a $165.00 target price on Alexion Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, November 14th. Credit Suisse Group set a $156.00 target price on Alexion Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, November 13th. BidaskClub upgraded Alexion Pharmaceuticals from a hold rating to a buy rating in a report on Friday, December 7th. Raymond James reiterated a buy rating on shares of Alexion Pharmaceuticals in a report on Friday, December 21st. Finally, Zacks Investment Research lowered Alexion Pharmaceuticals from a strong-buy rating to a hold rating in a report on Monday, December 31st. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Alexion Pharmaceuticals currently has a consensus rating of Buy and an average price target of $160.73.

Shares of Alexion Pharmaceuticals stock opened at $136.09 on Wednesday. The stock has a market capitalization of $30.41 billion, a PE ratio of 19.19, a PEG ratio of 1.00 and a beta of 1.55. Alexion Pharmaceuticals has a one year low of $92.56 and a one year high of $140.77. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.48 and a current ratio of 2.88.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Monday, February 4th. The biopharmaceutical company reported $2.14 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.54. Alexion Pharmaceuticals had a return on equity of 18.15% and a net margin of 1.88%. The company had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period in the previous year, the company posted $1.48 earnings per share. The company’s quarterly revenue was up 24.1% compared to the same quarter last year. Analysts predict that Alexion Pharmaceuticals will post 8.51 earnings per share for the current fiscal year.

In other Alexion Pharmaceuticals news, CAO Daniel Bazarko sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, February 14th. The stock was sold at an average price of $126.00, for a total transaction of $252,000.00. Following the transaction, the chief accounting officer now owns 5,020 shares of the company’s stock, valued at $632,520. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Ludwig Hantson sold 3,244 shares of the business’s stock in a transaction that occurred on Monday, December 31st. The stock was sold at an average price of $95.85, for a total value of $310,937.40. Following the transaction, the chief executive officer now directly owns 150,696 shares in the company, valued at approximately $14,444,211.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 8,488 shares of company stock worth $873,875. Company insiders own 4.35% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in ALXN. Russell Investments Group Ltd. increased its position in Alexion Pharmaceuticals by 13.1% during the third quarter. Russell Investments Group Ltd. now owns 59,222 shares of the biopharmaceutical company’s stock worth $8,222,000 after buying an additional 6,842 shares during the last quarter. Robeco Institutional Asset Management B.V. increased its position in Alexion Pharmaceuticals by 174.6% during the third quarter. Robeco Institutional Asset Management B.V. now owns 43,692 shares of the biopharmaceutical company’s stock worth $6,074,000 after buying an additional 27,782 shares during the last quarter. Cambridge Investment Research Advisors Inc. increased its position in Alexion Pharmaceuticals by 31.5% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 3,017 shares of the biopharmaceutical company’s stock worth $419,000 after buying an additional 722 shares during the last quarter. ING Groep NV acquired a new position in Alexion Pharmaceuticals during the third quarter worth approximately $2,978,000. Finally, SG Americas Securities LLC increased its position in Alexion Pharmaceuticals by 176.4% during the third quarter. SG Americas Securities LLC now owns 59,324 shares of the biopharmaceutical company’s stock worth $8,247,000 after buying an additional 37,864 shares during the last quarter. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Recommended Story: What is dollar cost averaging (DCA)?

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.